{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000045","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.259544+00:00","generated_at":"2026-05-22T12:33:36.001005+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026","bullets":["Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.","Research and development expenses $48.7M, up from $38.3M YoY, due to pipeline advancement.","Cash and cash equivalents $720.5M expected to fund operations into 2029.","Phase 1 KER-065 topline met objectives; plan to start Phase 2 in Q1 2026 after regulatory engagement.","Phase 2 TROPOS trial of cibotercept (KER-012) in PAH data expected Q2 2025; Board reviewing strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000045","json":"https://secwatch.observer/filing/0001664710-25-000045.json","markdown":"https://secwatch.observer/filing/0001664710-25-000045.md","text":"https://secwatch.observer/filing/0001664710-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/0001664710-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/kros-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:33:36.001005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}